Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous platelet-rich plasma + cross-linked hyaluronic acid
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraarticular, Subcutaneous, Intradermal
01
Overview
A combination therapy consisting of **autologous platelet-rich plasma (PRP)** and **cross-linked hyaluronic acid (HA)**, used primarily as an **injectable regenerative treatment** for degenerative joint disorders (such as osteoarthritis) and for various types of skin fibrosis and tissue repair. Platelet-rich plasma is derived from the patient's own blood and contains a high concentration of platelets that release growth factors promoting tissue healing, angiogenesis, and anti-inflammatory effects. Cross-linked hyaluronic acid is a modified polymer of naturally-occurring hyaluronic acid, designed for increased viscosity and longevity in tissues, serving as a space-filling, lubricating, and moisturizing agent. When combined, this mixture aims to both stimulate endogenous repair (via PRP’s growth factor release) and physically cushion/lubricate tissues (via HA’s viscoelastic/space-filling properties), yielding synergistic improvements in joint function and tissue elasticity.
- Brand names
- Regen Matrix-PRP-XLHA
- Other names
- autologous PRP + cross-linked hyaluronic acidPRP-HA combinationPRP-HA hybrid
02
Targets
Beyond the preview
Go deeper on autologous platelet-rich plasma + cross-linked hyaluronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous platelet-rich plasma + cross-linked hyaluronic acid.